Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix (HMTXF) received full Bahamas LARTA approval, including ethics approval, for its commercial Phase 1 VesCell study for angina, vascular dementia and pain.
The company is completing an initial C$380,500 private-placement closing, issuing 7,610,000 units at C$0.05 each, and seeks to raise up to $1,000,000. Each unit includes one share and half a warrant; whole warrants buy shares at C$0.12 for 24 months, subject to accelerated expiry. Final TSX Venture Exchange acceptance remains pending.
Hemostemix will not proceed with the proposed CytoImmune bioreactor licence; the transaction did not close and its contemplated 20 million shares were not issued. CytoImmune completed ACP-01 test batches outside the cleanroom and plans to move production inside. Hemostemix is preparing a second VesCell protocol to study longevity, including cognition, heart function and immune-health measures.
Hemostemix (HMTXF) will present at the Centurion One Capital Bahamas Summit, taking place October 19 to October 21, 2026.
Hemostemix plans to discuss VesCell commercialization in The Bahamas. It has applied under the country's Longevity and Regenerative Therapies Act for a treatment protocol covering a commercial Phase I basket trial of investigational VesCell (ACP-01) in angina, vascular dementia and pain. The release also describes one treated heart: its ejection fraction, the share of blood pumped per beat, rose from 13.2% to 20% three months after treatment. That observation is not presented as a result of the proposed trial.
Hemostemix (HMTXF) is filing Form 4B to seek price protection for the third tranche of its previously announced $1 million non-brokered placement.
The offering was first disclosed June 17, 2026, and remains subject to final TSX Venture Exchange acceptance. Each unit contains one common share and half a warrant. Each whole warrant permits the purchase of one share at CDN$0.12 for 24 months after the third tranche closes, subject to an early-expiry provision.
For the third tranche, Hemostemix expects approximately CDN$8,000 in cash finder fees and has issued 80,000 finder warrants. Proceeds are expected to support commercialization activities, ACP-01 production, regulatory filings in The Bahamas and working capital.
Hemostemix (OTCQB: HMTXF) announced commercialization of its proposed vascular cognitive impairment and vascular dementia clinical trial of VesCell™ (ACP-01) under the Bahamas Longevity and Regenerative Therapy Act (LARTA). Enrollment for the investigational trial is underway and remains subject to final LARTA approvals.
More than 130 participants have registered for a webinar by neurologist Dr. William R. Shankle on vascular dementia and the VesCell trial. According to Hemostemix, VesCell is an autologous endothelial progenitor cell therapy derived from a patient’s blood and has been used in 498 treatments, seven clinical trials (including two Phase II) and 318 subjects, with results published in 11 peer-reviewed papers. Prior ACP-01 work in chronic limb threatening ischemia reportedly showed 0% five-year mortality and wound healing in 83% of followed patients, but VesCell remains investigational and is not approved by the FDA or Health Canada for vascular dementia.
Hemostemix (OTCQB: HMTXF) appointed Prof. Dr. Ernst von Schwarz as Principal Investigator of its VesCell™ (ACP-01) longevity clinical trial, which will assess cardiovascular health, six‑minute walk distance, cognitive function and immune status as measures of health-span.
Dr. von Schwarz, a triple board-certified transplant surgeon, cardiologist and physician-scientist, has co-authored Hemostemix VesCell studies and is featured in the longevity-focused documentary HeartCode. Prior VesCell data include mean left ventricular ejection fraction rising from 14.6% to 28.4%, six‑minute walk gains of about 80 meters, significant reductions in myocardial perfusion defects, NYHA heart-failure class improvement, broad SF‑36 quality‑of‑life gains, and a long-term vascular dementia case report. Hemostemix reports seven completed clinical studies in 318 subjects and Phase II chronic limb‑threatening ischemia results with 0% mortality and wound healing in 83% of followed patients.
Hemostemix (OTCQB: HMTXF) closed the second tranche of its previously announced non-brokered private placement, raising aggregate gross proceeds of CDN$322,250 through the issuance of 6,445,000 units at CDN$0.05 per unit. Each unit includes one common share and one-half warrant; each whole warrant is exercisable at CDN$0.12 for 24 months, subject to an acceleration clause if the share price meets specified TSXV trading thresholds.
Hemostemix paid approximately CDN$21,780 in cash finder’s fees and issued 435,600 finder warrants exercisable at CDN$0.06 for 24 months. Proceeds are expected to fund sales, marketing, patient acquisition, physician education, ACP-01 production, Bahamian regulatory filings, and working capital. The TSXV extended the deadline to close the remaining CDN$1,000,000 of the placement to August 14, 2026, and the offering remains subject to final Exchange acceptance, with all securities under a four‑month‑plus‑one‑day hold.
Hemostemix (OTCQB: HMTXF) has drafted a commercial Phase I VesCell™ Longevity Clinical Trial protocol aimed at extending healthspan in healthy adults, measuring quality of life, muscle and cardiac performance, cognition, immune function, physical performance and functional independence.
The protocol builds on prior VesCell™/ACP-01 data, including statistically significant SF-36 quality-of-life gains across all eight domains in a 30-patient Phase I cardiomyopathy study, ~80-meter six-minute walk test improvements, increased left ventricular ejection fraction in severe cardiomyopathy, NYHA class improvement, and 0% mortality with 83% wound healing in a Phase II CLTI trial. The longevity protocol is under multidisciplinary scientific review before submission under The Bahamas' Longevity and Regenerative Therapies Act, with future updates to cover principal investigator appointment, regulatory acknowledgements, site activation, enrollment, Longevity Therapy Convertible Debenture sales and interim clinical/biomarker results.
Hemostemix (OTCQB:HMTXF) granted, in accordance with its stock option plan and subject to regulatory approval, a total of 6,280,000 stock options on July 22, 2026 to directors, officers, employees and consultants. Of these, 4,535,000 options vest immediately, while 1,745,000 options vest 50% on July 22, 2026 and 50% on July 22, 2027. Following this grant, Hemostemix reports 20,496,694 options issued and outstanding, including 3,140,000 options granted to directors and officers.
According to Hemostemix, the grants to insiders rely on valuation and minority-approval exemptions under MI 61-101, as the fair market value is below 25% of market capitalization. The company highlights its autologous stem cell therapy platform, seven completed clinical studies involving 318 subjects, eleven peer-reviewed publications, and Phase II data for ACP-01 in chronic limb threatening ischemia, including reported 0% mortality and wound healing in 83% of patients followed up to 4.5 years.
Hemostemix (OTCQB:HMTXF) filed a commercialization application under the Bahamas Longevity and Regenerative Therapies Act for a commercial Phase I basket trial of VesCell in vascular dementia, refractory angina and pain.
Prior studies showed statistically significant angina improvements and promising CLTI outcomes, supporting this physician-led, revenue-generating trial framework.
Hemostemix (OTCQB:HMTXF) closed the first tranche of its non-brokered private placement, raising CDN$360,000 through 7,200,000 units at CDN$0.05 per unit.
Each unit includes one share and half a warrant, supporting ACP-01 commercialization, regulatory filings in The Bahamas, and general working capital.